Comparative evaluation of eight in vitro pharmacodynamic models of infection: Activity of moxifloxacin against Escherichia coli and Streptococcus pneumoniae as an exemplary example

被引:6
|
作者
Dalhoff, Axel [1 ]
Bowker, Karen [2 ]
MacGowan, Alasdair [2 ]
机构
[1] Christian Albrechts Univ Kiel, Inst Infect Med, Brunswiker Str 4, D-24105 Kiel, Germany
[2] North Bristol NHS Trust, Bristol Ctr Antimicrobial Res & Evaluat, Southmead Hosp, Infect Sci, Bristol BS10 5NB, Avon, England
关键词
Pharmacodynamic model; Infection; Washout of bacteria; Immunocompetence; Inoculum preparation; BETA-LACTAM ANTIBIOTICS; INVITRO MODEL; ADSORPTION; SURFACE; BACTERIA; ADHESION; CULTURE; SERUM;
D O I
10.1016/j.ijantimicag.2019.09.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Use of pharmacodynamic in vitro models provides more clinically relevant information about the activities of antibiotics than static endpoints. Several models are used to simulate pharmacokinetics by dilution of the medium. It is discussed whether this procedure would result in a washout of bacteria, particularly if profiles with a short half-life are simulated. Methods have been developed to minimise the washout of bacteria. Bacteria are retained in the system either by centrifugation and resuspension, use of filters, a capillary unit, dialysis tubing or mathematical correction, versus systems with an unprotected outflow allowing a continuous washout of bacteria. None of these eight models has been directly compared with another. Therefore, an interlaboratory study was performed to address the question of whether or not washout matters. All laboratories used identical batches of media, bacteria, antibiotics and simulated pharmacokinetic profiles with a short or long half-life. Values of area under the bacterial kill-time curve (AUBKC), single-point kill rate and time to 3-log(10) reduction of inoculum were calculated. These parameters did not differ significantly between the models. Differences were noted if the inoculum was prepared from the early logarithmic growth phase compared with the late logarithmic or stationary growth phase, resulting either in a pronounced or reduced antibacterial activity. Thus, preparation of inocula affects the results generated, whereas washout of bacteria has apparently a negligible impact on antibacterial activities. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Comparison of the bactericidal activity of moxifloxacin and levofloxacin against staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae
    Lemmen, SW
    Häfner, H
    Klik, S
    Lütticken, R
    Zolldann, D
    [J]. CHEMOTHERAPY, 2003, 49 (1-2) : 33 - 35
  • [22] Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model
    Klepser, ME
    Ernst, EJ
    Petzold, CR
    Rhomberg, P
    Doern, GV
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 673 - 678
  • [23] Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae
    Kays, MB
    Conklin, M
    [J]. PHARMACOTHERAPY, 2000, 20 (11): : 1310 - 1317
  • [24] Evaluation of Ceftaroline Activity versus Ceftriaxone against Clinical Isolates of Streptococcus pneumoniae with Various Susceptibilities to Cephalosporins in an In Vitro Pharmacokinetic/Pharmacodynamic Model
    Steed, Molly E.
    Vidaillac, Celine
    Winterfield, Patricia
    Biek, Donald
    Rybak, Michael J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) : 2691 - 2695
  • [25] Comparison of faecal and optimal growth conditions on in vitro pharmacodynamic activity of marbofloxacin against Escherichia coli
    Pellet, T
    Gicquel-Bruneau, M
    Sanders, P
    Laurentie, M
    [J]. RESEARCH IN VETERINARY SCIENCE, 2006, 80 (03) : 324 - 335
  • [26] In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model
    Soon, Rachel L.
    Lenhard, Justin R.
    Bulman, Zackery P.
    Holden, Patricia N.
    Kelchlin, Pamela
    Steenbergen, Judith N.
    Friedrich, Lawrence V.
    Forrest, Alan
    Tsuji, Brian T.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 49 (01) : 25 - 30
  • [27] Pharmacokinetic and pharmacodynamic evaluation of nitrofurantoin against Escherichia coli in a murine urinary tract infection model
    Maaland, Marit Gaastra
    Jakobsen, Lotte
    Guardabassi, Luca
    Frimodt-Moller, Niels
    [J]. APMIS, 2024, 132 (07) : 492 - 498
  • [28] The effect of albumin globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli
    Rubinstein, E
    Diamantstein, L
    Yoseph, G
    Gruzman, G
    Rubinovitch, B
    Barzilai, A
    Keller, N
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (12) : 678 - 681
  • [29] Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae
    Frédénucci, I
    Chomarat, M
    Bercion, R
    Carricajo, A
    Celard, M
    Croizé, J
    Delubac, F
    Fèvre, D
    Fuhrmann, C
    Helfre, M
    Letouzey, MN
    Lelièvre, H
    Mandjee, A
    Marthelet, P
    Meley, R
    Perrier-Gros-Claude, JD
    Ros, A
    Roure, C
    Smati, S
    Thierry, J
    Tous, J
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (10) : 680 - 683
  • [30] Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model
    Garrison, MW
    Malone, CL
    Eiland, JE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) : 1545 - 1547